緩釋心血管藥物市場

發達國家心血管疾病的患病率和發病率持續上升，為心血管疾病治療的開發者帶來了挑戰和機遇。心血管疾病的治療藥物大多是口服即刻製劑，但由於與藥物安全性和患者依從性有關的問題，能夠提高藥物安全性和減少給藥次數的製劑受到關注。

目錄

• 緩釋心血管藥物
• 執行摘要
• 心血管治療-市場力學
• 心腦血管用藥情況
• 心血管臨床治療的未滿足需求
• 推動心血管藥物需求的因素
• 人口變化
• 不斷發展的製藥技術
• 管理式醫療計劃
• 擴大自我管理
• 緩釋技術
• 口語
• 先進的覆膜系統
• 珠子系統
• 雙層平板電腦
• 三層平板
• 微型平板電腦
• 經皮
• 心血管緩釋產品分析
• 心血管治療藥物商業化的因素
• CR 治療的心血管部分
• 心絞痛
• 膽固醇管理
• 心律失常
• 高血壓
• 外周動脈疾病
• 市場因素
• 監管和批准
• 美國 (FDA)
• 歐盟（歐洲、中東和非洲）
• 日本 (PMDA)
• 澳大利亞 (TGA)
• 管理式護理和醫療保健經濟學
• 進入該行業的公司簡介

The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to drug safety and patient compliance have focused attention on formulations that can improve drug safety profiles and reduce dosing frequency. Important treatment segments for controlled release cardiovascular drugs include angina, hypertension, arrhythmias, cholesterol, and peripheral artery disease. Important growth factors for controlled release cardiovascular drugs include evolving patient demographics, environmental and lifestyle causative factors, increased public awareness of cardiovascular conditions and their associated morbidities, and expanded patient access to cardiovascular treatment services.

What You Will Learn:

• Analyzes and evaluates controlled release cardiovascular drug products and assesses the market potential for existing and probable future products

• Analyzes product strategies, technologies and market development issues

• Provides detailed analysis of cardiovascular market segments, market demographics, and therapeutic strategies

• Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations

• Evaluates the impact of economic, technology, and regulatory factors on cardiovascular drug markets

Table of Contents

• Controlled Release Cardiovascular Therapeutics
• Executive Summary
• Cardiovascular Therapeutics - Market Dynamics
• The Cardiovascular Drug Landscape
• Unmet Needs in Cardiovascular Clinical Treatment
• Cardiovascular Drug Demand Drivers
• Demographic Shifts
• Evolving Drug Formulation Technology
• Managed Care Initiatives
• Growth in Self Administration
• Modified Release Technologies
• Oral
• Advanced Film Coating Systems
• Bead Systems
• Bi-layer Tablets
• Tri-layer Tablets
• Microtablets
• Transdermal
• Cardiovascular Controlled Release Product Analysis
• Cardiovascular Drug Commercialization Factors
• Cardiovascular Segments for CR Therapeutics
• Angina
• Cholesterol Management
• Heart Rhythm
• Hypertension
• Peripheral Artery Disease
• Market Factors
• Regulations and Approvals
• US (FDA)
• EU (EMEA)
• Japan (PMDA)
• Australia (TGA)
• Managed Care and Healthcare Economics
• Sector Participant Company Profiles